Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12188/9502
Title: PROGNOSTIC VALUE OF MOLECULAR MARKER ON OUTCOME IN PATIENTS WITH HIGH-GRADE GLIOMA. SINGLE INSTITUTIONAL EXPERIENCE
Authors: Stojkovski, Igor 
Klisarovska, Violeta 
Chakalaroski, Petar 
Dzundeva, Jasmina
Ivanova, Maja
Petreska, Bojana
Keywords: Chemoradiotherapy
Glioma
Molecular Characterization
Issue Date: Oct-2020
Publisher: Department of Anaesthesia and Reanimation, Faculty of Medicine, “Ss. Cyril and Methodius” University Skopje, R.N.Macedonia
Journal: Macedonian Journal of Anaesthesia, A Journal on Anaesthesiology, Resuscitation, Analgesia and Critical Care
Abstract: High-grade glioma (HGG) are among the most frequent primary brain tumors. Prognosis in HGG depends on histology, age, performance status, and other patient and tumor related factors. The 2016 revision of the WHO Classification of CNS Tumors introduced molecular characterization of HGG, with possible impact on prognosis. Analysis of a total of 49 patients with HGG with known MGMT methylation status and IDH1 and IDH2 mutation has been done. All patients undergo surgery, followed by concurrent chemoradiotherapy and adjuvant chemotherapy with temozolomide. Median follow up of all patients was 21,3 months (6,2-52,1 months). The Median Disease-free survival (DFS) was 20,3 months, and the median overall survival (OS) was calculated as 21,8 months. Patients has been stratified according to MGMT methylation status and IDH1 and IDH2 mutation status. DFS and OS have been compared between groups. The assessment shows 2-year DFS and OS were 45,5% and 54% for methylated and 40,4% and 47,8 for unmethylated patients. 2-year DFS and OS were 75% and 86% for IDH1 mutated patients and 34,12% and 47,1% for IDH1 unmutated patients. Two-year DFS and OS were 56% and 83% for IDH 2 mutated patients and 28,8% and 40,9% for IDH2 unmutated patients. There were suggestions for favorable prognostic factor for both MGMT methylation and IDH1 and IDH2 mutation, but we did not show any statistically significant difference of DFS and OS between MGMT methylated and unmethylated patients and between IDH1 and IDH2 mutated and unmutated patients due to small specimen and relatively short follow up.
URI: http://hdl.handle.net/20.500.12188/9502
ISSN: 2545-4366
Appears in Collections:Faculty of Medicine: Journal Articles

Files in This Item:
File Description SizeFormat 
HGG_Prognostic.pdf3.28 MBAdobe PDFView/Open
Show full item record

Page view(s)

26
checked on May 11, 2021

Download(s)

10
checked on May 11, 2021

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.